Samuel Aparicio

Samuel Aparicio MB, BCH, PhD, FRCPath, FRSC

Chief Scientific Officer

Dr. Aparicio graduated in medical and natural sciences from Cambridge University (UK) and clinical medicine from Oxford University (UK). He trained in internal medicine and anatomic pathology. From 2000-2005, Dr. Aparicio was a senior investigator in the Department of Oncology, Cambridge. He co-founded (1999) the UK and Singapore-based biotech company Paradigm Therapeutics (now Takeda Cambridge), where he was Director of Science until 2004. Dr. Aparicio is currently the Nan and Lorraine Robertson Chair of Breast Cancer Research, based at UBC/BC Cancer Agency, Vancouver, Canada, and a Canada Research Chair in Molecular Oncology. His work encompasses the fields of cancer evolution, single-cell genomics, mouse genetic models, high throughput screens, and translational breast cancer research.